HCPLive Network
Latest Oncology Headlines
By Wayne Kuznar
In the first pivotal phase III study of a Janus-associated kinase (JAK) inhibitor for the treatment of polycythemia vera (PV), ruxolitinib (Jakafi) was superior to best available therapy (BAT) in maintaining control of hematocrit without the need for phlebotomy and in reducing spleen size in patients with an inadequate response to or intolerance of hydroxyurea.
There has been a decrease in the number of uninsured following the open enrollment period of the Affordable Care Act, according to a report published online July 23 in the New England Journal of Medicine.
Most suitable candidates in the United States who need a bone marrow transplant can find an acceptable match through the National Marrow Donor Program, according to a new study.
Young cancer patients and survivors may have gynecologic concerns, which should be managed before, during, and after treatment, according to a Committee Opinion published in the August issue of Obstetrics & Gynecology.
Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.
Aspirin may be less preferable to other anticoagulants following hip fracture repair, but may be favored after elective knee or hip arthroplasty, according to a meta-analysis published online July 17 in the Journal of Hospital Medicine.
By Raoul S. Concepcion, MD
I am sure that those of you who attended the AUA meeting in Orlando were struck by the number of presentations on the use of biomarkers and their role in better risk stratification and management of the urologic oncology patient.
The mammalian target of rapamycin complex pathway seems to be involved in antiphospholipid syndrome-associated vascular lesions, according to a study published in the July 24 issue of the New England Journal of Medicine.
By Tony Berberabe, MPH
Keeping your practice financially solvent is difficult because of the uncertainty of regulatory and reform mandates, electronic health records requirements, and diminishing reimbursements. But a type of care delivery, called concierge care, is making some inroads in the primary care arena—and may hold some usefulness in oncology practice.
Blood donations to the American Red Cross are down substantially, and the agency says an "emergency situation" could arise within weeks.
For women with stage I or II breast cancer without a BRCA mutation, contralateral prophylactic mastectomy is associated with an absolute 20-year survival benefit of less than 1%, according to a study published online July 16 in the Journal of the National Cancer Institute
By Silas Inman
The FDA has approved idelalisib in combination with rituximab for patients with high-risk relapsed or refractory CLL and as a single-agent for two types of iNHL.
For women undergoing hysterectomy by morcellation, the prevalence of uterine cancers is 27 per 10,000, with increased prevalence with advanced age, according to a research letter published online July 22 in the Journal of the American Medical Association.
By Silas Inman
Extended adjuvant treatment with neratinib (PB272, HKI-272) significantly extended improved disease-free survival (DFS) compared with placebo for patients with HER2-positive breast cancer who received prior adjuvant trastuzumab
Patient reviews indicate that the attributes most valued in physicians include interpersonal skills and bedside manner, according to a report published online July 16 by Vitals.
By Prasad S. Adusumilli, MD
Although malignant pleural mesothelioma (MPM) remains a rare disease, Memorial Sloan Kettering Cancer Center has considerable experience with this malignancy, and our specialists are at the forefront of translating new approaches for the treatment of patients with mesothelioma into the clinic.
By Wayne Kuznar
Cabozantinib added to erlotinib has antitumor activity in heavily pretreated patients with EGFR-positive non–small cell lung cancer (NSCLC) whose disease progressed on erlotinib alone, according to the results of a phase II trial presented at the 2014 ASCO Annual Meeting.
By Silas Inman
The FDA has assigned a priority review designation to bevacizumab (Avastin) in combination with chemotherapy for patients with recurrent platinum-resistant ovarian cancer.
By Joseph Burns
For the past 10 years, John Sprandio, MD, has been standardizing care delivery processes for cancer patients.
By Silas Inman
The combination of the immunotherapy CRS-207 and the vaccine GVAX Pancreas has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic pancreatic cancer.
Physician's Money Digest
A new car’s resale value automatically drops as soon as it is driven off the lot, but some retain their value a lot better than others.
Although a majority of Americans are consistently surprised by their medical bills, the experiences differ greatly by state.